<b>Effects of Probucol Versus Aspirin and Versus Brachytherapy on Restenosis After Femoropopliteal Angioplasty:</b>The PAB Randomized Multicenter Trial

Gallino, Augusto; Do, Dai-Do; Alerci, Mario; Baumgartner, Iris; Cozzi, Luca; Segatto, Jeanne Marie; Bernier, Jacques; Tutta, Paolo; Kellner, Frauke; Triller, Jürgen; Schneider, Ernst; Amann-Vesti, Beatrice; Studer, G.; Jäger, K; Aschwanden, Markus; Canevascini, Reto; Jacob, Augustinus Ludwig; Kann, Roger; Greiner, Richard; Mahler, F

doi:10.1583/04-1269mr.1

Cited by 34 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gallino et al 82 reported results of a 2 ϫ 2 factorial randomized trial of 335 patients assigned to PTA, PTA plus BT (14 Gy), PTA plus probucol, or PTA plus probucol and BT. No late thrombotic reocclusion occurred after PTA and subsequent BT.…”

Section: Brachytherapymentioning

confidence: 99%

Current state of endovascular treatment of femoro-popliteal artery disease

Zeller

2007

Vasc Med

114

View full text Add to dashboard Cite

Considerable advances have been made over the last decade in percutaneous technology for the treatment of atherosclerotic diseases in the femoro-popliteal arteries. While treatment strategies are well defined in the iliac segment, where angioplasty and stenting perform well in appropriately selected lesions, the search for a durable transcatheter therapy for femoro-popliteal lesions continues. Whereas balloon angioplasty (PTA) is the accepted therapy for short lesions, long diffuse lesions are still recommended for surgical treatment. However, attractive new technologies ranging from transcatheter plaque excision to laser ablation, rotational atherectomy, cryoplasty, brachytherapy, and placement of drug-eluting stents to simple angioplasty with drug-coated balloons may have the potential to replace femoro-popliteal bypass surgery as a treatment of choice for complex lesions. This article reviews the status of percutaneous endovascular techniques for the treatment of femoro-popliteal artery occlusive disease.Key words: angioplasty; percutaneous intervention; peripheral occlusive disease; popliteal artery; stent; superficial femoral artery Albert-Ludwigs-University Freiburg, Freiburg, Germany and Department of Angiology, Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany Address for correspondence: Thomas Zeller, Abteilung Angiologie, Herz-Zentrum Bad Krozingen, Südring 15, D-79189 Bad Krozingen, Germany. Tel: ϩ49 7633/4020; Fax: ϩ49 7633/402-8208; E-mail: thomas.zeller@herzzentrum.de defined as target lesion revascularization (TLR). If another lesion at the target vessel site but not the index lesion itself needs to be treated during follow-up this intervention is defined as target vessel revascularization (TVR). Superficial femoral artery and popliteal artery diseaseThe superficial femoral artery (SFA) extending to the proximal popliteal artery segment is the most commonly diseased vasculature. More than 50% of all PAD cases involve the SFA and popliteal artery. Femoro-popliteal disease is often characterized by long, diffuse lesions, long occlusions (as opposed to mild focal stenoses). The unique slow-flow and highresistance environment in the femoro-popliteal region creates a milieu that seems to increase the prevalence of de novo disease. The same issues that lead to accumulation of plaque within the femoro-popliteal region likely amplify the response to injury and may explain the high incidence of restenosis following traditional angioplasty. 9 Femoro-popliteal occlusive disease is still the Achilles heel of the vascular specialist.The durability of femoro-popliteal intervention can be predicted by the pre-procedural angiographic characteristics of the target lesion. The TASC I and the updated TASC II document 6 divided the femoropopliteal lesions into four categories (Table 1). TASC A lesions are more suitable for endovascular procedures, whereas surgery is recommended for TASC D lesions. The TASC document clearly states that it takes more evidence to make firm recommendations about the role of an...

show abstract

Section: Brachytherapymentioning

confidence: 99%

Current state of endovascular treatment of femoro-popliteal artery disease

Zeller

2007

Vasc Med

114

View full text Add to dashboard Cite

show abstract

“…Krueger et al [29] reported a significant reduction of restenosis following PTA of de novo lesions in the femoropopliteal area in the brachytherapy group compared to the control group. Gallino et al [15] also stressed the beneficial effect of endovascular brachytherapy in fighting restenosis (17% restenosis rates in the brachytherapy group vs. 35% in the patients without brachytherapy; p < 0.001). However, they pointed out that they observed late thrombotic occlusions exclusively in six of 133 patients of the brachytherapy group versus none in the control group.…”

Section: Discussionmentioning

confidence: 98%

Früheffekte einer Rhenium-188-Behandlung auf Proliferation, Migration und Matrixsynthese humaner aortaler glatter Muskelzellen in vitro

Kehlbach¹,

Dittmann

Schmid³

et al. 2006

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…24,25 In the femoral segment, acute stent thrombosis within the first 6 months occurred in 21% to 27% of the patients receiving nitinol stents and EVBT. 17,26 In both reports, late acute stent thrombosis was synchronous with reduction of the double antiplatelet regimen. For this reason, many authors recommend double antiplatelet therapy for at least 1 year to prevent late thrombotic occlusions after EVBT.…”

Section: ¤ ¤mentioning

confidence: 97%

Endovascular Brachytherapy Using Liquid Beta-Emitting Rhenium-188 for the Treatment of Long-Segment Femoropopliteal In-Stent Stenosis

Werner

Scheinert

Henn

et al. 2012

Journal of Endovascular Therapy

View full text Add to dashboard Cite

show abstract

Effects of Probucol Versus Aspirin and Versus Brachytherapy on Restenosis After Femoropopliteal Angioplasty:The PAB Randomized Multicenter Trial

Abstract: Endovascular brachytherapy significantly reduces restenosis, improves symptoms, and reduces reinterventions after PTA of femoropopliteal arteries. Probucol reduces restenosis but has no additive effect when combined with brachytherapy.

Cited by 34 publications

References 31 publications

Current state of endovascular treatment of femoro-popliteal artery disease

Current state of endovascular treatment of femoro-popliteal artery disease

Früheffekte einer Rhenium-188-Behandlung auf Proliferation, Migration und Matrixsynthese humaner aortaler glatter Muskelzellen in vitro

Endovascular Brachytherapy Using Liquid Beta-Emitting Rhenium-188 for the Treatment of Long-Segment Femoropopliteal In-Stent Stenosis

Contact Info

Product

Resources

About